Health CarePharmaceuticals & Biotechnology
  • Price (DKK)239.70
  • Today's Change-2.80 / -1.15%
  • Shares traded294.58k
  • 1 Year change-2.60%
  • Beta1.4018
Data delayed at least 15 minutes, as of Feb 25 2021 15:59 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

  • Revenue in DKK (TTM)17.67bn
  • Net income in DKK1.58bn
  • Incorporated1950
  • Employees5.63k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Bavarian Nordic A/S1.91bn606.31m13.34bn649.0016.112.5315.026.9714.1714.1741.4690.120.31864.6020.945,906,361.0010.09-2.8212.11-3.6147.6066.7931.68-9.591.5445.190.4102--32.33-11.454.19--27.95--
Recipharm AB (publ)8.17bn250.10m13.69bn7.38k67.033.2012.771.683.473.47122.5172.740.62543.376.79--1.911.422.221.6348.3848.033.062.521.213.770.5819--48.4326.71-1.259.518.56--
AddLife AB3.89bn381.75m13.87bn988.0037.1010.1823.663.564.614.6147.0316.801.426.337.56--14.01--24.45--34.48--9.86--0.603151.690.299--51.55--268.42------
Vaccibody AS63.44k-118.21m16.88bn36.00--152.42--266,126.80-2.29-2.290.00080.53340.0004--0.00843,625.00-67.04-27.40-72.25-29.59-----186,331.00-16,364.47----0.00--279.57---50.42------
ALK-Abello A/S3.49bn25.00m26.60bn2.45k1,161.879.1099.247.622.262.26316.19288.520.63141.367.341,426,645.000.4522-0.33170.5498-0.396858.0958.940.7161-0.53221.213.060.2302--6.636.33150.00-40.812.21--
Swedish Orphan Biovitrum AB (publ)11.27bn2.40bn31.33bn1.47k12.802.048.062.7810.9110.9151.2968.520.32491.344.07--6.919.758.3512.2278.8675.4121.2621.680.48987.370.4190.007.1136.44-1.79118.6692.40--
Orion Oyj8.01bn1.63bn37.30bn3.42k22.416.7518.164.651.571.577.685.211.001.756.09--20.4420.1725.1425.5660.3860.2720.4020.822.27155.610.129397.082.581.209.731.10-1.192.90
H. Lundbeck A/S17.67bn1.58bn48.29bn5.63k30.492.8414.982.737.957.9588.9085.420.47661.914.513,140,
Data as of Feb 25 2021. Currency figures normalised to H Lundbeck A/S's reporting currency: Danish Krone DKK

Institutional shareholders

6.10%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 20192.49m1.25%
Invesco Advisers, Inc.as of 30 Sep 20202.00m1.00%
The Vanguard Group, Inc.as of 31 Jan 20211.64m0.82%
BlackRock Fund Advisorsas of 04 Feb 20211.54m0.78%
BlackRock Advisors (UK) Ltd.as of 17 Feb 2021905.91k0.46%
Dimensional Fund Advisors LPas of 04 Feb 2021840.94k0.42%
Handelsbanken Fonder ABas of 31 Jan 2021801.12k0.40%
Nordea Investment Management AB (Denmark)as of 30 Nov 2020733.04k0.37%
UBS Asset Management Switzerland AGas of 02 Feb 2021620.44k0.31%
Danske Bank A/S (Investment Management)as of 19 Feb 2021571.12k0.29%
More ▼
Data from 31 Dec 2019 - 19 Feb 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.